英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbott laboratories ltd - dopamine hydrochloride - solution for injection - 1.6mg/1ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbott laboratories ltd - dopamine hydrochloride - solution for injection - 3.2mg/1ml

美国 - 英文 - NLM (National Library of Medicine)

hf acquisition co. llc, dba health first - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hcl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hcl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hcl, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hcl. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. clinical studies have shown that when dopamine hcl is administered before urine flow has diminished to levels of approximately 0.3 ml/minute, prognosis is more favorable. nevertheless, in a number of oliguric or anuric patients, administration of dopamine hcl has resulted in an increase in urine flow, which in some cases reached normal levels. dopamine hcl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. it should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. low cardiac output – increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. increase in cardiac output has been associated with either static or decreased systemic vascular resistance (svr). static or decreased svr associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. in many instances the renal fraction of the total cardiac output has been found to increase. increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. hypotension – hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine hcl which have little effect on svr. at high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished svr. as in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. therefore, it is suggested that the physician administer dopamine hcl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. dopamine hcl should not be used in patients with pheochromocytoma. dopamine hcl should not be administered to patients with uncorrected tachyarrhythmias or ventricular fibrillation.

美国 - 英文 - NLM (National Library of Medicine)

energique, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - may temporarily relieve symptoms associated with reactions to dopamine.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. may temporarily relieve symptoms associated with reactions to dopamine.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dopamine hydrochloride 40 mg/ml;   - solution for injection - 200 mg/5ml - active: dopamine hydrochloride 40 mg/ml   excipient: sodium metabisulfite water for injection - latest regulatory activity

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

max health limited - dopamine hydrochloride 40 mg/ml - solution for injection - 200 mg/5ml - active: dopamine hydrochloride 40 mg/ml excipient: hydrochloric acid nitrogen sodium hydroxide sodium metabisulfite water for injection - for the correction of haemodynamic imbalance present in: acute hypotension or shock associated with myocardial infarction, endotoxic septicaemia, trauma and renal failure. as an adjunct after open heart surgery, where there is persistent hypotension after correction of hypovolaemia. in chronic cardiac decompensation as in congestive failure.

美国 - 英文 - NLM (National Library of Medicine)

deseret biologicals, inc. - taraxacum officinale (unii: 39981fm375) (taraxacum officinale - unii:39981fm375), goldenseal (unii: zw3z11d0jv) (goldenseal - unii:zw3z11d0jv), melatonin (unii: jl5dk93rcl) (melatonin - unii:jl5dk93rcl), dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), serotonin hydrochloride (unii: gkn429m9vs) (serotonin - unii:333do1rdjy) - dopamine hydrochloride – brain fatigue, travel sickness, hydrastis canadensis – brain fog, l-dopa – poor concentration, melatonin – jet lag, serotonin (hydrochloride) – anxiety, stress, taraxacum officinale – mood swings • for the temporary relief of symptoms including: • brain fatigue • brain fog • anxiety • poor concentration • jet lag • mood swings • stress • travel sickness these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

马来西亚 - 英文 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga lifescience sdn. bhd. - dopamine hydrochloride -

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

hospira uk ltd - dopamine hydrochloride - concentrate for soln for inf - 160 mg/ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - dopamine hydrochloride - solution for infusion - 160mg/1ml